Raidium Introduces AI Imaging Platform for U.S. Cancer Centers
Raidium announced in a press release the U.S. launch of its AI imaging platform, Raidium Read. The tool is designed to improve oncology imaging workflows by combining multiple radiology functions in one interface. It is already deployed at Moffitt Cancer Center, where it replaces a legacy radiomics solution.
The Raidium Read platform supports whole body lesion detection, AI segmentation models, and lesion tracking across follow up and prior studies. It is initially available for use in oncology research and clinical trials, pending regulatory clearance for routine clinical use.
According to Raidium, the system reduces manual workload, improves consistency in image interpretation, and facilitates collaboration between radiologists and clinicians. The company is pursuing 510(k) clearance for selected features and expects to complete this process by the end of 2026. Cancer centers can register for access through the company's invitation program.
Raidium operates from Paris and Silicon Valley, focusing on integrating foundation models with unified clinical viewers for radiology applications.
We hope you enjoyed this article.
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from: Life Sciences
Subscribe to Life AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Market report
AI’s Time-to-Market Quagmire: Why Enterprises Struggle to Scale AI Innovation
The 2025 AI Governance Benchmark Report by ModelOp provides insights from 100 senior AI and data leaders across various industries, highlighting the challenges enterprises face in scaling AI initiatives. The report emphasizes the importance of AI governance and automation in overcoming fragmented systems and inconsistent practices, showcasing how early adoption correlates with faster deployment and stronger ROI.
Read more